HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine.

Abstract
Nicotinic acetylcholine receptor (nAChR) blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some treatment-resistant patients; however, it is not known whether these effects are independent, or whether the two neurotransmitter systems act synergistically. We first determined that the SSRI fluoxetine and the nicotinic partial agonist cytisine have synergistic effects in a mouse model of antidepressant efficacy, whereas serotonin depletion blocked the effects of cytisine. Using a pharmacological approach, we found that the 5-HT1A agonist 8-OH-DPAT also potentiated the antidepressant-like effects of cytisine, suggesting that this subtype might mediate the interaction between the serotonergic and cholinergic systems. The 5-HT1A receptors are located both presynaptically and postsynaptically. We therefore knocked down 5-HT1A receptors in either the dorsal raphe (presynaptic autoreceptors) or the hippocampus (a brain area with high expression of 5-HT1A heteroreceptors sensitive to cholinergic effects on affective behaviors). Knockdown of 5-HT1A receptors in hippocampus, but not dorsal raphe, significantly decreased the antidepressant-like effect of cytisine. This study suggests that serotonin signaling through postsynaptic 5-HT1A receptors in the hippocampus is critical for the antidepressant-like effects of a cholinergic drug and begins to elucidate the molecular mechanisms underlying interactions between the serotonergic and cholinergic systems related to mood disorders.
AuthorsYann S Mineur, Emily B Einstein, Matthew P Bentham, Mattis B Wigestrand, Sam Blakeman, Sylvia A Newbold, Marina R Picciotto
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology) Vol. 40 Issue 4 Pg. 938-46 (Mar 2015) ISSN: 1740-634X [Electronic] England
PMID25288485 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Alkaloids
  • Antidepressive Agents
  • Azocines
  • Quinolizines
  • Serotonin Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Receptor, Serotonin, 5-HT1A
  • cytisine
  • 8-Hydroxy-2-(di-n-propylamino)tetralin
Topics
  • 8-Hydroxy-2-(di-n-propylamino)tetralin (pharmacology)
  • Alkaloids (therapeutic use)
  • Animals
  • Antidepressive Agents (therapeutic use)
  • Azocines (therapeutic use)
  • Disease Models, Animal
  • Drug Synergism
  • Fluoxetine (therapeutic use)
  • Gene Expression Regulation (drug effects)
  • HEK293 Cells
  • Hindlimb Suspension
  • Hippocampus (drug effects, metabolism)
  • Humans
  • Interpersonal Relations
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Motor Activity (drug effects)
  • Quinolizines (therapeutic use)
  • Receptor, Serotonin, 5-HT1A (genetics, metabolism)
  • Serotonin Receptor Agonists (pharmacology)
  • Selective Serotonin Reuptake Inhibitors (therapeutic use)
  • Stress, Psychological (drug therapy, etiology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: